Claims for Patent: 8,057,807

Summary for Patent: 8,057,807

Title:	Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction
Abstract:	The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
Inventor(s):	Schmidt; Richard A. (Arvada, CO)
Assignee:	The Regents of the University of Colorado, a body corporate (Boulder, CO)
Application Number:	12/243,659
Patent Claims:	1. A method for treating a recalcitrant voiding dysfunction, the method comprising the step of injecting a botulinum toxin to a bladder wall of a patient with a recalcitrant voiding dysfunction, thereby treating the recalcitrant voiding dysfunction. 2. The method of claim 1, wherein the patient is a human. 3. The method of claim 1, wherein the patient is a human female. 4. The method of claim 1, wherein the patient is a human male. 5. The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A. 6. The method of claim 1, wherein a symptom of the recalcitrant voiding dysfunction is urinary incontinence. 7. A method for treating a recalcitrant voiding dysfunction, the method comprising the step of injecting a therapeutically effective amount of botulinum toxin type A to a bladder wall of a patient with a recalcitrant voiding dysfunction, thereby treating the recalcitrant voiding dysfunction. 8. The method of claim 7, wherein the therapeutically effective amount of botulinum toxin type A is injected in the amount up to 2500 units. 9. The method of claim 7, wherein the therapeutically effective amount of botulinum toxin type A is about 1.4 IU/kg to 17.1 IU/kg of botulinum toxin type A. 10. The method of claim 7, wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A. 11. The method of claim 7, wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A. 12. A method for treating a recalcitrant voiding dysfunction in a patient in need thereof, the method comprising the step of administering a botulinum toxin type A, in an amount of up to 2500 units, to a bladder wall of a patient with a recalcitrant voiding dysfunction, thereby treating the recalcitrant voiding dysfunction of the patient with a recalcitrant voiding dysfunction. 13. The method of claim 12, wherein the botulinum toxin type A is administered in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, a powder, a cream, an emulsion, a pill, a troche, a suppository, a suspension, and a solution. 14. The method of claim 12, wherein administration of the botulinum toxin results in an increase in bladder capacity of the patient. 15. The method of claim 14, wherein bladder capacity is increased to about 300 to 400 cubic centimeters post-administration. 16. The method of claim 12, wherein the patient is a human.

Details for Patent 8,057,807

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	December 09, 1991	8,057,807	2017-07-15
Abbvie Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	December 09, 1991	8,057,807	2017-07-15

International Patent Family for US Patent 8,057,807

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9903483
United States of America	9066943
United States of America	8840905
United States of America	8062643
United States of America	7968104
United States of America	7470431